Treatment & control of benign prostatic hyperplasia (BPH) & for the prevention of urologic events to reduce the risk of acute urinary retention, of surgery including transurethral resection of the prostate (TURP) & prostatectomy. Causes regression of enlarged prostate, improves urinary flow & symptoms associated w/ BPH.
Carefully monitor patients w/ large residual urine vol &/or severely diminished urinary flow for obstructive uropathy. Initial & periodic digital rectal exams as well as other evaluations for prostate cancer are recommended prior to initiating therapy. Decrease in PSA levels by approx 50% in patients w/ BPH; consider decrease in serum PSA levels when evaluating PSA data & does not rule out concomitant prostate cancer. May cause abnormalities of the external genitalia of a male fetus when administered to pregnant woman.